EP3405101A1 — Differential diagnosis of ectopic cushing's syndrome
Assigned to Corcept Therapeutics Inc · Expires 2018-11-28 · 7y expired
What this patent protects
Improved methods and systems for differentially diagnosing ACTH-dependent Cushing's syndrome are provided herein. Treatment methods can use glucocorticoid receptor antagonists, which differentially affects the ratio of cortisol to ACTH levels in patients having Cushing's Disease …
USPTO Abstract
Improved methods and systems for differentially diagnosing ACTH-dependent Cushing's syndrome are provided herein. Treatment methods can use glucocorticoid receptor antagonists, which differentially affects the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for differentially diagnosing ACTH-dependent Cushing's syndrome can include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a glucocorticoid receptor antagonist (GRA) according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.
Drugs covered by this patent
- Mifeprex (MIFEPRISTONE) · Corcept Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.